Promoting Health through Vitamin D Therapeutics

Improving People's Lives by Treating and Preventing the Clinical Consequences of
Vitamin D Insufficiency and Secondary Hyperparathyroidism

 

Recent News:

OPKO Presents Data on RAYALDEE® at ASN Kidney Week 2016
November 17, 2016

FDA Approves New Drug Application for RAYALDEE® to Treat Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Stage 3-4 Chronic Kidney Disease
June 21, 2016

OPKO Announces Appointment of Douglass Laidlaw as Vice President of Medical Affairs
May 11, 2016

 
     
 

 

 

© 2016 OPKO Health Inc.- All rights reserved. | Privacy Policy | Terms Of Use